Teva to pay $1.2bn in FTC ‘pay-for-delay’ case

Israel-based pharmaceutical company Teva will have to fork out $1.2 billion after a long-running dispute with the US Federal Trade Commission (FTC) over a controversial ‘pay-for-delay’ case was settled.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

AI is transforming top 100 innovators, shows index

23 January 2026 Just one pharma company is recognised in a report that lists the most world's most inventive countries and companies.

Americas

Novartis win blocks generics relitigating $7.8bn heart drug patent

22 January 2026 A district court judge shuts down a Novartis rival from reopening validity and infringement arguments over an Entresto patent.

Americas

Rooted rights: Lessons from plant patent infringement and invalidity cases

22 January 2026 From public use and foreign sales to the challenges of proving infringement, plant patents present unique legal opportunities—and pitfalls—for the agricultural industry, explain Bree Vculek, Gaby Longsworth, and Robert Millonig of Sterne Kessler.

More features

AI is transforming top 100 innovators, shows index

Novartis win blocks generics relitigating $7.8bn heart drug patent

Leading the arena: WIPR identifies the top US trade secrets specialists of 2025

Rooted rights: Lessons from plant patent infringement and invalidity cases

Cadwalader global head among trio moving to Orrick

Skinny labels, big stakes: SCOTUS lines up the case of the year

Chinese biotech strikes billion dollar deal in nextgen cancer race

$5.4bn medtech leader fails to bury a rival's patent

Teva to pay $1.2bn in FTC ‘pay-for-delay’ case

More on this story

Editor's picks

Editor's picks

More features